Copyright Reports & Markets. All rights reserved.

Global PD-1 and PD-L1 Immunotherapy Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by PD-1 and PD-L1 Immunotherapy Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global PD-1 and PD-L1 Immunotherapy Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 PD-1 inhibitor
    • 1.4.3 PD-L1 inhibitor
  • 1.5 Market by Application
    • 1.5.1 Global PD-1 and PD-L1 Immunotherapy Market Share by Application: 2020 VS 2026
    • 1.5.2 Solid Tumors
    • 1.5.3 Blood-related Tumors
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Global Growth Trends by Regions

  • 2.1 PD-1 and PD-L1 Immunotherapy Market Perspective (2015-2026)
  • 2.2 PD-1 and PD-L1 Immunotherapy Growth Trends by Regions
    • 2.2.1 PD-1 and PD-L1 Immunotherapy Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 PD-1 and PD-L1 Immunotherapy Historic Market Share by Regions (2015-2020)
    • 2.2.3 PD-1 and PD-L1 Immunotherapy Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 PD-1 and PD-L1 Immunotherapy Market Growth Strategy
    • 2.3.6 Primary Interviews with Key PD-1 and PD-L1 Immunotherapy Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top PD-1 and PD-L1 Immunotherapy Players by Market Size
    • 3.1.1 Global Top PD-1 and PD-L1 Immunotherapy Players by Revenue (2015-2020)
    • 3.1.2 Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global PD-1 and PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global PD-1 and PD-L1 Immunotherapy Market Concentration Ratio
    • 3.2.1 Global PD-1 and PD-L1 Immunotherapy Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by PD-1 and PD-L1 Immunotherapy Revenue in 2019
  • 3.3 PD-1 and PD-L1 Immunotherapy Key Players Head office and Area Served
  • 3.4 Key Players PD-1 and PD-L1 Immunotherapy Product Solution and Service
  • 3.5 Date of Enter into PD-1 and PD-L1 Immunotherapy Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global PD-1 and PD-L1 Immunotherapy Historic Market Size by Type (2015-2020)
  • 4.2 Global PD-1 and PD-L1 Immunotherapy Forecasted Market Size by Type (2021-2026)

5 PD-1 and PD-L1 Immunotherapy Breakdown Data by Application (2015-2026)

  • 5.1 Global PD-1 and PD-L1 Immunotherapy Market Size by Application (2015-2020)
  • 5.2 Global PD-1 and PD-L1 Immunotherapy Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America PD-1 and PD-L1 Immunotherapy Market Size (2015-2020)
  • 6.2 PD-1 and PD-L1 Immunotherapy Key Players in North America (2019-2020)
  • 6.3 North America PD-1 and PD-L1 Immunotherapy Market Size by Type (2015-2020)
  • 6.4 North America PD-1 and PD-L1 Immunotherapy Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe PD-1 and PD-L1 Immunotherapy Market Size (2015-2020)
  • 7.2 PD-1 and PD-L1 Immunotherapy Key Players in Europe (2019-2020)
  • 7.3 Europe PD-1 and PD-L1 Immunotherapy Market Size by Type (2015-2020)
  • 7.4 Europe PD-1 and PD-L1 Immunotherapy Market Size by Application (2015-2020)

8 China

  • 8.1 China PD-1 and PD-L1 Immunotherapy Market Size (2015-2020)
  • 8.2 PD-1 and PD-L1 Immunotherapy Key Players in China (2019-2020)
  • 8.3 China PD-1 and PD-L1 Immunotherapy Market Size by Type (2015-2020)
  • 8.4 China PD-1 and PD-L1 Immunotherapy Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan PD-1 and PD-L1 Immunotherapy Market Size (2015-2020)
  • 9.2 PD-1 and PD-L1 Immunotherapy Key Players in Japan (2019-2020)
  • 9.3 Japan PD-1 and PD-L1 Immunotherapy Market Size by Type (2015-2020)
  • 9.4 Japan PD-1 and PD-L1 Immunotherapy Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia PD-1 and PD-L1 Immunotherapy Market Size (2015-2020)
  • 10.2 PD-1 and PD-L1 Immunotherapy Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia PD-1 and PD-L1 Immunotherapy Market Size by Type (2015-2020)
  • 10.4 Southeast Asia PD-1 and PD-L1 Immunotherapy Market Size by Application (2015-2020)

11 India

  • 11.1 India PD-1 and PD-L1 Immunotherapy Market Size (2015-2020)
  • 11.2 PD-1 and PD-L1 Immunotherapy Key Players in India (2019-2020)
  • 11.3 India PD-1 and PD-L1 Immunotherapy Market Size by Type (2015-2020)
  • 11.4 India PD-1 and PD-L1 Immunotherapy Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America PD-1 and PD-L1 Immunotherapy Market Size (2015-2020)
  • 12.2 PD-1 and PD-L1 Immunotherapy Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America PD-1 and PD-L1 Immunotherapy Market Size by Type (2015-2020)
  • 12.4 Central & South America PD-1 and PD-L1 Immunotherapy Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 AstraZeneca
    • 13.1.1 AstraZeneca Company Details
    • 13.1.2 AstraZeneca Business Overview and Its Total Revenue
    • 13.1.3 AstraZeneca PD-1 and PD-L1 Immunotherapy Introduction
    • 13.1.4 AstraZeneca Revenue in PD-1 and PD-L1 Immunotherapy Business (2015-2020))
    • 13.1.5 AstraZeneca Recent Development
  • 13.2 Bristol-Myers Squibb
    • 13.2.1 Bristol-Myers Squibb Company Details
    • 13.2.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
    • 13.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Introduction
    • 13.2.4 Bristol-Myers Squibb Revenue in PD-1 and PD-L1 Immunotherapy Business (2015-2020)
    • 13.2.5 Bristol-Myers Squibb Recent Development
  • 13.3 F. Hoffmann-La Roche
    • 13.3.1 F. Hoffmann-La Roche Company Details
    • 13.3.2 F. Hoffmann-La Roche Business Overview and Its Total Revenue
    • 13.3.3 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Introduction
    • 13.3.4 F. Hoffmann-La Roche Revenue in PD-1 and PD-L1 Immunotherapy Business (2015-2020)
    • 13.3.5 F. Hoffmann-La Roche Recent Development
  • 13.4 Merck
    • 13.4.1 Merck Company Details
    • 13.4.2 Merck Business Overview and Its Total Revenue
    • 13.4.3 Merck PD-1 and PD-L1 Immunotherapy Introduction
    • 13.4.4 Merck Revenue in PD-1 and PD-L1 Immunotherapy Business (2015-2020)
    • 13.4.5 Merck Recent Development
  • 13.5 Pfizer
    • 13.5.1 Pfizer Company Details
    • 13.5.2 Pfizer Business Overview and Its Total Revenue
    • 13.5.3 Pfizer PD-1 and PD-L1 Immunotherapy Introduction
    • 13.5.4 Pfizer Revenue in PD-1 and PD-L1 Immunotherapy Business (2015-2020)
    • 13.5.5 Pfizer Recent Development
  • 13.6 Roche
    • 13.6.1 Roche Company Details
    • 13.6.2 Roche Business Overview and Its Total Revenue
    • 13.6.3 Roche PD-1 and PD-L1 Immunotherapy Introduction
    • 13.6.4 Roche Revenue in PD-1 and PD-L1 Immunotherapy Business (2015-2020)
    • 13.6.5 Roche Recent Development
  • 13.7 Novartis
    • 13.7.1 Novartis Company Details
    • 13.7.2 Novartis Business Overview and Its Total Revenue
    • 13.7.3 Novartis PD-1 and PD-L1 Immunotherapy Introduction
    • 13.7.4 Novartis Revenue in PD-1 and PD-L1 Immunotherapy Business (2015-2020)
    • 13.7.5 Novartis Recent Development
  • 13.8 Jiangsu HengRui Medicine
    • 13.8.1 Jiangsu HengRui Medicine Company Details
    • 13.8.2 Jiangsu HengRui Medicine Business Overview and Its Total Revenue
    • 13.8.3 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Introduction
    • 13.8.4 Jiangsu HengRui Medicine Revenue in PD-1 and PD-L1 Immunotherapy Business (2015-2020)
    • 13.8.5 Jiangsu HengRui Medicine Recent Development
  • 13.9 Innovent
    • 13.9.1 Innovent Company Details
    • 13.9.2 Innovent Business Overview and Its Total Revenue
    • 13.9.3 Innovent PD-1 and PD-L1 Immunotherapy Introduction
    • 13.9.4 Innovent Revenue in PD-1 and PD-L1 Immunotherapy Business (2015-2020)
    • 13.9.5 Innovent Recent Development
  • 13.10 Eli Lilly
    • 13.10.1 Eli Lilly Company Details
    • 13.10.2 Eli Lilly Business Overview and Its Total Revenue
    • 13.10.3 Eli Lilly PD-1 and PD-L1 Immunotherapy Introduction
    • 13.10.4 Eli Lilly Revenue in PD-1 and PD-L1 Immunotherapy Business (2015-2020)
    • 13.10.5 Eli Lilly Recent Development
  • 13.11 GlaxoSmithKline
    • 10.11.1 GlaxoSmithKline Company Details
    • 10.11.2 GlaxoSmithKline Business Overview and Its Total Revenue
    • 10.11.3 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Introduction
    • 10.11.4 GlaxoSmithKline Revenue in PD-1 and PD-L1 Immunotherapy Business (2015-2020)
    • 10.11.5 GlaxoSmithKline Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    This report focuses on the global PD-1 and PD-L1 Immunotherapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the PD-1 and PD-L1 Immunotherapy development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

    The key players covered in this study
    AstraZeneca
    Bristol-Myers Squibb
    F. Hoffmann-La Roche
    Merck
    Pfizer
    Roche
    Novartis
    Jiangsu HengRui Medicine
    Innovent
    Eli Lilly
    GlaxoSmithKline

    Market segment by Type, the product can be split into
    PD-1 inhibitor
    PD-L1 inhibitor
    Market segment by Application, split into
    Solid Tumors
    Blood-related Tumors

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    The study objectives of this report are:
    To analyze global PD-1 and PD-L1 Immunotherapy status, future forecast, growth opportunity, key market and key players.
    To present the PD-1 and PD-L1 Immunotherapy development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
    To strategically profile the key players and comprehensively analyze their development plan and strategies.
    To define, describe and forecast the market by type, market and key regions.

    In this study, the years considered to estimate the market size of PD-1 and PD-L1 Immunotherapy are as follows:
    History Year: 2015-2019
    Base Year: 2019
    Estimated Year: 2020
    Forecast Year 2020 to 2026
    For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

    Buy now